AbbVie Norway’s Kirsti Nyhus discusses access challenges in the Norwegian market for innovative drugs, the importance of bringing clinical trials back to Norway, managing through the COVID-19 pandemic, and establishing an award-winning working culture.
Norway has the opportunity to use its registries, pilot pay for performance schemes, and initiate innovative contracting, so that payment is only made when something works, uncertainty is removed, and patients can access the best treatment possible
